Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Carboplatin for Recurrent or Refractory Retinoblastoma
NCT02792036Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin in retinoblastoma (Rb), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Dose-Limiting Toxicity at 5 months. Started Nov 2016; status: completed.
02
Drugs
carboplatin
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT02792036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792036.